BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1
495 results:

  • 1. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
    Ichimura N; Urata Y; Kobayashi T; Hibi H
    Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced nras-mutant melanoma.
    Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
    Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
    [TBL] [Abstract] [Full Text] [Related]  

  • 3.
    Sfreddo HJ; Koh ES; Zhao K; Swartzwelder CE; Untch BR; Marti JL; Roman BR; Dublin J; Wang RS; Xia R; Cohen JM; Xu B; Ghossein R; Givi B; Boyle JO; Tuttle RM; Fagin JA; Wong RJ; Morris LGT
    Thyroid; 2024 Apr; 34(4):450-459. PubMed ID: 38407967
    [No Abstract]    [Full Text] [Related]  

  • 4. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
    Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
    Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
    Lee M; Morris LG
    Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
    Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
    J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort.
    Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
    Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
    Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
    Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A mutation panel comprising BRAF
    Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
    Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genomic profiling of primary and metastatic thyroid cancers.
    Máximo V; Melo M; Zhu Y; Gazzo A; Sobrinho Simões M; Da Cruz Paula A; Soares P
    Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 38015791
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
    Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
    Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Sialadenoma papilliferum-like intraductal papillary tumour: an emerging entity with intercalated duct differentiation showing MAPK pathway activation in both ductal and myoepithelial cells.
    Oh KY; Kim JH; Hong SD; Yoon HJ
    Pathology; 2024 Feb; 56(1):52-58. PubMed ID: 37973455
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent nras and CTNNB1 mutations.
    Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
    Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Pitfall in Thyroid Practice.
    Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
    Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification.
    Zhou Y; Wu X; Zhang Y; Li Z; Ge X; Chen H; Mao Y; Ding W
    PeerJ; 2023; 11():e16054. PubMed ID: 37744220
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clear Cell Squamous Cell Carcinoma of the Maxillary Gingiva Associated with PIK3CA and HRAS Mutations: Report of a Case and Literature Review.
    Hirose K; Shibahara T; Teramoto A; Usami Y; Ono S; Iwamoto Y; Murakami S; Oya K; Uzawa N; Motooka D; Hori Y; Morii E; Toyosawa S
    Head Neck Pathol; 2023 Dec; 17(4):1026-1033. PubMed ID: 37735286
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
    Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
    Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Analysis of BRAF and nras mutations in thyroid tumors in patients from Argentina].
    Repetto EM; Fernandez L; Lambertini R; Del Valle Jaen A; Ruda Vega V; Moldes S; Lutfi R; Aranda C; Faure E; Oneto A
    Medicina (B Aires); 2023; 83(4):505-513. PubMed ID: 37582124
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, nras, and KIT mutations.
    Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
    Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 25.